Androgen status in non-diabetic elderly men with heart failure

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
   PubMed Web of Science ®Google Scholar
• Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589– 598.
   PubMed Web of Science ®Google Scholar
• Loncar G, Springer J, Anker M, et al. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle. 2016;7:246–260.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114:1829–1837.
   PubMed Web of Science ®Google Scholar
• Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, et al. Androgen treatment and muscle strength in elderly men: a meta-analysis. J Am Geriatr Soc. 2006;54:1666.
   PubMed Web of Science ®Google Scholar
• Loncar G, Fülster S, von Haehling S, et al. Metabolism and the heart: an overview of muscle, fat, and bone metabolism in heart failure. Int J Cardiol. 2013;162:77–85.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Kaczmarek A, Francis DP, et al. Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure. Circulation. 2006;114:126–134.
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–2556.
   PubMed Web of Science ®Google Scholar
• Lafontan M, Viguerie N. Role of adipokines in the control of energy metabolism: focus on adiponectin. Curr Opin Pharmacol. 2006;6:580–585.
   PubMed Web of Science ®Google Scholar
• Kalicińska E, Wojtas K, Majda J, et al. Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?. Aging Male. 2013;16:123–131.
   PubMed Web of Science ®Google Scholar
• Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34:1669–1675.
   PubMed Web of Science ®Google Scholar
• Basaria S. Male hypogonadism. Lancet. 2014;383:1250–1263.
   PubMed Web of Science ®Google Scholar
• Matsue Y, Suzuki M, Nakamura R, et al. Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. Circ J. 2011;75:2833e2839.
   Web of Science ®Google Scholar
• Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol. 2017;120:S37–S47.
   PubMed Web of Science ®Google Scholar
• Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–1053.
   PubMed Web of Science ®Google Scholar
• Trippel T, Lenk J, Gunga HC, et al. Estimating fat mass in heart failure patient. Arch Med Sci Atheroscler Dis. 2016;1:e1–e12.
   Google Scholar
• Maisel A, Mueller C, Adams K, Jr et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824–839.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017. pii: S0735-1097(17)37087-0. [Epub ahead of print]. doi:10.1016/j.jacc.2017.04.025
   Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672.
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724–731.
   PubMed Web of Science ®Google Scholar
• Wu FC, EMAS Group, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–135.
   PubMed Web of Science ®Google Scholar
• Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–534.
   PubMed Web of Science ®Google Scholar
• Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol. 1997;30:997–1001.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Jones TH, Channer KS. Testosterone in chronic heart failure. Front Horm Res. 2009;37:183–196.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16:581–606.
   PubMed Web of Science ®Google Scholar
• Pasquali R, Casimirri F, Cantobelli S, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metab Clin Exp. 1991;40:101–104.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84:3673–3680.
   PubMed Web of Science ®Google Scholar
• Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756–1762.
   PubMed Web of Science ®Google Scholar
• Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226–228.
   PubMed Web of Science ®Google Scholar
• Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and Cox-2-dependent mechanisms. Nat Med. 2005;11:1096–1103.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Clarke S, Channer KS, et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2007;156:595–602.
   PubMed Web of Science ®Google Scholar
• Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073–18080.
   PubMed Web of Science ®Google Scholar
• Güder G, Frantz S, Bauersachs J, et al. Low circulating androgens and mortality risk in heart failure. Heart. 2010; 96:504–509.
   PubMed Web of Science ®Google Scholar
• Volterrani M, Rosano G, Iellamo F. Testosterone and heart failure. Endocrine. 2012;42:272–277.
   PubMed Web of Science ®Google Scholar
• Josiak K, Jankowska EA, Piepoli MF, et al. Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones. J Cachexia Sarcopenia Muscle. 2014;5:287–296.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Filippatos G, Ponikowska B, et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Cardiac Fail. 2009;15:442–450.
   PubMed Web of Science ®Google Scholar
• Iellamo F, Sala-Mercado JA, Ichinose M, et al. Spontaneous baroreflex control of heart rate during exercise and muscle metaboreflex activation in heart failure. Am J Physiol Heart Circ Physiol. 2007;293:H1929–H1936.
   PubMed Web of Science ®Google Scholar
• Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54:919–927.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006;27:57–64.
   PubMed Web of Science ®Google Scholar
• Dos Santos MR, Sayegh AL, Bacurau AV, et al. Effect of exercise training and testosterone replacement on skeletal muscle wasting in patients with heart failure with testosterone deficiency. Mayo Clin Proc. 2016;91:575–586.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. Aging Male. 2014;17:63–65.
   PubMed Web of Science ®Google Scholar
• Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–2058.
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725–733.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Zitzmann M, Traish AM, et al. Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions. Mayo Clin Proc. 2016;91:881–896.
   PubMed Web of Science ®Google Scholar
• Wu HY, Wang XF, Wang JH, et al. Testosterone level and mortality in elderly men with systolic chronic heart failure. Asian J Androl. 2011;13:759–763.
   PubMed Web of Science ®Google Scholar